Entire-body PET Scans for Multiple Sclerosis

• Status: Not yet recruiting
• Trial end date: 2022-03-01
• Target enrollment: 0
• Participant gender: All

Summary

To evaluate whether an entire-body positron emission tomography (PET) scanner can be exploited to improve evaluation, monitoring and measurement of both peripheral and central demyelination in multiple sclerosis (MS) patients.

• Phase: Early Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Brain Health Alliance
• Treatments: Radiopharmaceuticals

Criteria

Inclusion Criteria:

• Multiple sclerosis (MS) patients with advanced state of the disease as evidenced by severe disability scores (EDSS > 5) with impaired motor control of extremities.

• Normal healthy subjects.

• Willing and able to lie motionless on the PET-CT scanner bed for at least 10 minutes and up to 20 minutes for the duration of the PET-CT medical imaging scan.

Exclusion Criteria:

• Any additional complicating medical illness other than MS including any other neuropsychiatric illness unrelated to MS diagnosed prior to the onset of initial symptoms of MS.

• Pregnancy or breast feeding.

• Diabetes or other metabolic-endocrine disorders.

• Any known concomitant acute infection.

• History of metastatic or locally invasive cancer.

• Recent surgery, chemotherapy or radiation therapy.